Pharmacology of anticoagulants used in the treatment of venous thromboembolism
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S
Hirsh J, Bauer KA, Donati MB et al (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:141–159
Weitz DS, Weitz JI (2010) Update on Heparin: what do we need to know? J Thromb Thombolysis 29:199–207
Bick R (2005) Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin N Am 19:1–51
Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109–1114
Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 119:874–881
Rosborough TK, Shepherd MF (2004) Achieving target anti-factor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 24:713–719
Schulman S, Beth RJ et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:257–298
Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879
Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e24S–e43S
Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184S
Campbell NR, Hull RD, Brant R et al (1996) Aging and heparin-related bleeding. Arch Intern Med 156:857–860
Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350S
Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712
Protamine sulfate injection. AHFS Drug Information 2015. American Society of Health-System Pharmacists, Bethesda
Selleng K, Warkentin TE et al (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35(4):1165–1176
Martel N, Lee J, Wells PS et al (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715
Warkentin TE, Kelton JG (2001) Temporal aspects of Heparin-induced thrombocytopenia. N Engl J Med 344:1286–1292
Warkentin TE, Greinacher A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:340–380
Fareed J, Hoppensteadt D, Walenga J, Igbal O, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043–1057
Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(Suppl 1):31–38
Lovenox (enoxaparin sodium injection) prescribing information. Sanofi Aventis U.S. LLC, Bridgewater. http://products.sanofi.us/lovenox/lovenox.html . Accessed 11 August 2015
Fragmin (dalteparin sodium for subcutaneous injection) prescribing information. Pfizer Injectables. New York. http://labeling.pfizer.com/ShowLabeling.aspx?id=2293 . Accessed 11 August 2015
Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083
Collignon F, Fryman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J et al (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–640
Hasan K, Lazo-Langner A, Acedillo R, Zeller M, Hackam DG (2010) Anticoagulant response after dalteparin overdose. J Thromb Haemost 8:2321–2323
Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C et al (2005) High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost 11:127–138
Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H et al (2002) The pharmacokinetics of fondaparinux sodium in health volunteers. Clin Pharmacokinet 41(Suppl 2):1–9
Arixtra (fondaparinux sodium solution for subcutaneous injection) prescribing information. GlaxoSmithKline. Research Triangle Park. http://www.gsk.ca/english/docs-pdf/product-monographs/Arixtra.pdf . Accessed 11 August 2015
Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772
Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE et al (2006) Effect of fondaparinux on coagulation assays: results of college of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605–1611
Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S–e151S
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th Edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 141(suppl 2):e44s–e88s
Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists. American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl 6):160s–198s
Stirling Y (1995) Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coag Fibrinolysis 6:361–375
Breckenridge A, Orme M, Wessling H et al (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430
Hignite C, Uetriecht J, Tschanz C et al (1980) Kinetics of R and S warfarin enantiomers. Clin Pharmacol Ther 28:99–105
Chan E, McLachlan AJ, Pegg M et al (1994) Disposition of warfarin enantiomers and metabolism in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563–569
Warfarin Prescribing Information. Bristol-Myers Squibb. Princeton. http://packageinserts.bms.com/pi/pi_coumadin.pdf . Accessed 11 August 2015
Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65(4):365–375
Limdi NA, McGwin G, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321
Cavallari LH, Langaee TY, Momary KM et al (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87(4):459–464
Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013–1021
Ng VL (2009) Anticoagulation monitoring. Clin Lab Med 28:283
Ng VL (2009) Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 28:253
Kirkwood TB (1983) Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 49:238–244
Hirsh J, Poller L (1994) The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 154:282–288
Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K (1995) The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. Am J Clin Pathol 103:358–365
Spinler SA, Nutescu ED, Smythe MA et al (2005) Anticoagulation monitoring Part 1:warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 39:1049–1055
Wittkowsky AK (2006) Drug interactions with oral anticoagulants. In: Colman RW, Marder VJ, Clowes AW et al (eds) Hemostasis and thrombosis. Basic principals and clinical practice. 5th ed. Lippincott Williams & Wilkins, Philadelphia
Hansten P, Horn J (2010) Drug interactions analysis and management. Wolters Kluwer, St Louis
Daly AK, Aithal GP (2003) Genetic regulation of warfarin metabolism and response. Semin Vasc Med. 3:231–237
Pradaxa (dabigatran etexilate mesylate) prescribing information. Boehringer Ingelheim. Ridgefield. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf . Accessed 12 August 2015
Eliquis (apixaban prescribing information). Bristol-Myers Squibb Company. Princeton, NJ and Pfizer Inc. New York. http://packageinserts.bms.com/pi/pi_eliquis.pdf . Accessed 11 August 2015
Savaysa (edoxaban prescribing information). Daiichi Sankyo Inc., Parsippany. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true . Accessed 13 August 2015
Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals. Titusville. https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf . Accessed 11 August 2015
Hellwig T, Gulseth M (2013) New oral therapies for the prevention and treatment of venous thromboembolism. AJHP 70:113–125
Cabral KP (2013) Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis 36:133–140
Funk DMA (2012) Coagulation assays and anticoagulant monitoring. ASH Education Book 1:460–465
Tripodi A, Siegal DM, Crowther MA, Garcia DA (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035
Cuker A (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. JACC 64:1128–1139
Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16S
Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268
Van Ryn J, Stangier J, Haerrter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Throm Haemost 103:1116–1127
Baglin T, Hillarp A, Tripodi A et al (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. JTH 11:756–760
Frost C, Nepal S, Wang J et al (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76(5):776–786
Frost C, Yu Z, Shenker A, Nepal S (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: Abstract presentations: IXth world conference on clinical pharmacology and therapeutics. Can J Clin Pharmacol 15:e469. July 27, 2008 to August 1, 2008, Quebec City
Raghavan N, Frost C, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81
Frost C, Yu Z, Nepal S et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132
Frost C, Wang X, Barrett, et al. (2009) Abstracts of the XXII congress of the international society of thrombosis and haemostasis, Boston, July 2009. JTH abstract vol 7 (suppl 2): PP-MO-407
Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. BJCP 76:908–916
Frost C, Wang J, Li C et al (2009) Single-does safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther 85(suppl 1):s34
Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16
Kubitza D, Roth A, Becka M et al (2013) Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 76:89–98
Bounameaux H, Camm AJ (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74:1209–1231
Becker RC, Yang H, Barrett Y et al (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 32:183–187
Bathala MS, Masumoto H, Oguma T et al (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab and Disp 40:2250–2255
Fuji T, Fujita S, Abe Y et al (2013) Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. J Thromb Haemost 11(Suppl 2):556
Parasrampuria D, Matsushima N, Chen S et al (2013) Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis. J Thromb Haemost 11(Suppl 2):225
Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13(5):331–342
Morishima Y, Kamisato C et al (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 143(2):241–247